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ABSTRACT 
Tuberculosis (TB) is a leading cause of death worldwide, causing more deaths than HIV/AIDS. 
A TB patient can have pulmonary or extrapulmonary TB or both. South Africa has a high 
incidence rate of TB, recording 834 cases per 100 000 population in 2015, compared to 142 
per 100 000 globally. Loss to follow-up (LTFU) rates during TB treatment in South Africa 
have ranged from 7% to 30%.  
 
The factors associated with LTFU can be divided into four groups: socioeconomic factors, 
patient-related factors, treatment factors, and health system or programmatic factors. 
Socioeconomic factors include a lack of support and a low socioeconomic status. Patient-
related factors include substance abuse, beliefs and low TB knowledge, while treatment factors 
include side effects and a history of LTFU. Among health system or programmatic factors that 
contribute to LTFU are a poor relationship with the healthcare workers and large treatment 
programmes.  
 
Studies to determine the factors associated with LTFU in HIV-uninfected TB patients are few 
as most studies have focused on HIV/TB co-infected patients. Co-infected patients make up 
almost 60% of TB patients. The aim of this study was to determine the demographic and 
clinical factors associated with LTFU in HIV-uninfected TB patients who registered for TB 
treatment in Ekurhuleni North sub-district from 1st January 2011 to 30th June 2012. LTFU was 
defined as a lack of a documented treatment outcome among TB patients who should have 
completed TB treatment based on TB treatment start date. 
 
The study was a retrospective cohort study involving the secondary analysis of routine TB 
treatment data collected from 18 primary care clinics in Ekurhuleni North sub-district. The 
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participants were described at the beginning of TB treatment using clinical and demographic 
data. The treatment duration and outcomes were also described. The burden of LTFU was 
determined. Univariate and multivariate logistic regression and Cox proportional hazards 
regression were used to determine the factors associated with LTFU. In addition, survival 
analysis was conducted to determine if there was a difference in the time to LTFU among HIV-
uninfected TB patients based on clinical and demographic factors. Sensitivity analysis of the 
multivariate logistic regression and Cox proportional hazards regression was carried out to 
compare the results obtained when follow-up was restricted to 8 months to those obtained for 
12 months of follow-up. Sensitivity analysis was also conducted around the definition of 
LTFU. The impact on the results of multivariate logistic regression after assuming that 
participants who had a missing treatment outcome in the primary study were not lost to follow-
up was determined. 
 
Five hundred and fifteen participants were included in the analysis. The median age of the 
participants was 33 years (IQR: 26-47). Fifty-eight percent of the participants were male. 
Pulmonary TB was the most common form of TB among the participants. The rate of treatment 
success was 77.67% and that of LTFU was 17.28%. Of those lost to follow-up, 60 had a missing 
treatment outcome and 29 had default as an outcome in the primary study. The median length 
of treatment was 6.39 months (IQR: 5.67-7.44), and the median time to LTFU was 3.67 months 
(IQR: 1.54-6.33). Eighty-two percent of the participants had a documented change of treatment 
phase. Clinics with a high patient burden had a similar proportion of poor outcomes (death, 
LTFU and treatment failure) to clinics with low patient burdens. Significant differences in 
change of treatment phase and length of treatment were observed between those lost to follow-
up and those not lost to follow-up.  
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LTFU took place throughout TB treatment, with a steady increase in the probability of LTFU 
over the first 6 months of follow-up. None of the factors investigated had a significant effect 
on time to LTFU. Following logistic regression and Cox proportional hazards regression 
analyses, none of the factors assessed were significantly associated with LTFU. Sensitivity 
analysis showed that censoring the participants at 8 months did not change the results of the 
logistic regression analysis. For Cox proportional hazards regression, female participants had 
a 5% lower risk of LTFU compared to male participants in the 12-month analysis. In the 8-
month analysis, female participants had a 5% higher risk of LTFU. When participants with a 
missing treatment outcome were not considered lost to follow-up, sex was found to be 
significantly associated with LTFU. Female participants had a 66% lower risk of LTFU 
compared to male participants. 
 
A limitation of the use of secondary data in this study was that the study question asked in this 
study was different from the question that was asked in the primary study. As a result, the 
variables collected in the primary study were different from the variables required in this study. 
Information on socioeconomic status, residence type, comorbidities, treatment clinics and 
health system factors was not available. 
 
None of the factors investigated in this study were significantly associated with LTFU in HIV-
uninfected TB patients in Ekurhuleni North sub-district. The factors influencing LTFU in 
Ekurhuleni North may not have been investigated in this study. More studies need to be 
conducted with a wide range of variables in Ekurhuleni North to determine the factors that 
influence LTFU among HIV-uninfected TB patients.   
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Tuberculosis (TB) is one of the leading causes of death, causing more deaths globally than the 
Human Immunodeficiency Virus (HIV) (Khan et al., 2016). TB is caused by Mycobacterium 
tuberculosis (Tola et al., 2015). TB can involve either the lungs (pulmonary TB) or other parts 
of the body (extrapulmonary TB (EPTB)). Approximately five to ten percent of those exposed 
to TB bacilli will develop TB disease at some point in their life, with differences in strain 
virulence, age, genetics and nutritional status accounting for differences in disease 
susceptibility (Neyrolles and Quintana-Murci, 2009). Poor people are disproportionately 
affected as they are exposed to poor living conditions and social deprivation that increase their 
risk of disease (Wood et al., 2010).  
 
TB data is essential to quantify the burden of the disease to enable appropriate action to be 
taken. TB data is collected annually by the WHO from all of its member countries through 
national surveys and surveillance (WHO, 2016). Issues with data collection, particularly in 
remote areas, may result in underreporting. In South Africa, surveillance is good but can be 
compromised by incomplete information in different parts of the South African National TB 
Surveillance System (Podewils et al., 2015).  
 
In 2015, there were 10.4 million new TB cases and 1.4 million deaths due to TB worldwide 
(WHO, 2016). An estimated 56% of TB cases were among men and 90% among adults 
(Chandra and Mishra, 2017). The global, African and South African TB incidence rates were 
142, 275 and 834 cases per 100 000 population respectively in 2015 (WHO, 2016). Global and 
African statistics show that the mortality rate due to TB was higher in HIV-uninfected TB 
patients than in HIV-infected TB patients (WHO, 2016). The higher mortality rates in HIV-
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uninfected TB patients may be due to HIV-uninfected patients not presenting for care as early 
as HIV-infected patients due to lower knowledge and less stigma. In addition, HIV-uninfected 
TB patients may not be prioritised in TB training programs. In South Africa, mortality was 
approximately 300% higher in HIV-infected TB patients compared to HIV-uninfected patients 
(WHO, 2016). The overall TB mortality rate in South Africa was 179 deaths per 100 000 
population, compared to 24 and 75 deaths per 100 000 population worldwide and in Africa 
respectively in the same year (WHO, 2016).  
 
Previous studies in South Africa have found that LTFU ranged from 7% to 30%, with rates 
higher than 20% being observed in studies involving patients with drug-resistant TB (Brust et 
al., 2010, Gafar et al., 2014, Kendall et al., 2013, Kigozi et al., 2017, Pepper et al., 2012). In 
2015, treatment success rates in South Africa stood at 78%, which was lower than the African 
and worldwide rates of 81% and 83% respectively (WHO, 2016). Approximately 1.8% of the 
new cases and 6.7% of the retreatment cases were multidrug-resistant TB (MDR-TB) cases 
(WHO, 2015). 
 
Successful TB treatment is crucial to decrease the burden of TB as unsuccessful TB treatment 
will result in increased contact rates in communities which will in turn fuel the spread of TB. 
The Directly Observed Treatment, Short Course (DOTS) strategy is the main TB treatment 
strategy used in South Africa (Kigozi et al., 2017), and has been in use since 1997 (Churchyard 
et al., 2014). The strategy, which is efficient and cost effective, is recommended globally for 
TB control programmes (WHO, 2017b).  
 
DOTS has five components: continuous financial commitment and political will, the use of 
sputum-smear microscopy for diagnosis, the administration of a standardised short course of 
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TB treatment with supportive and direct observation, a constant stock of high quality anti-TB 
drugs and the standardisation of case recording and reporting to monitor individual and 
programme performance (WHO, 2017a, WHO, 2017b). The goals of DOTS are to ensure that 
patients complete TB treatment and to stop the development of drug resistance in communities 
(Davies, 2003). Through ensuring an effective drug supply and management system, DOTS 
helps to ensure that national TB programmes do not have to deny patients care due to 
inadequate drug stocks (WHO, 2017b). 
 
Isoniazid, rifampicin, pyrazinamide and ethambutol are the first-line drugs used for the 
treatment of drug-susceptible TB (Kasozi et al., 2015). TB treatment involves two months of 
intensive therapy using pyrazinamide, isoniazid, rifampicin, and ethambutol, followed by a 
continuation phase (four months) using rifampicin and isoniazid (Budgell et al., 2016). In 
severe or complicated cases of EPTB, the continuation phase may last for seven months (SA 
Department of Health, 2014). A new, shorter regimen for the treatment of MDR-TB lasts nine 
to twelve months unless there is resistance to second line drugs (WHO, 2016). Treatment for 
extremely drug-resistant TB (XDR-TB) lasts for 24 months (Caminero et al., 2010).  
 
According to the WHO, TB treatment outcomes can be cure and treatment completion 
(classified as treatment success or ideal outcomes), or treatment failure, death and lost to 
follow-up (classified as bad outcomes), or not evaluated, which are described below for 
treatment in patients with drug susceptible TB (WHO, 2014): 
 
• Cure: Occurs when a patient starts treatment with bacteriological confirmation of 
disease and is smear or culture negative in the final treatment month and on a minimum 
of one previous occasion.  
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• Treatment completion: Occurs when a patient completes his/her treatment with no 
sign of being unsuccessful and sputum test results are unavailable.  
• Treatment failure: Occurs when a patient’s smear or culture is positive at any point 
from five months after the start of treatment. 
• Death: Death due to any cause while undergoing TB treatment. 
• Lost to follow-up: Occurs when a patient either does not begin treatment or has his/her 
treatment interrupted for at least two consecutive months. 
• Not evaluated: Occurs when the treatment outcome is not assigned. This may be due 
to the patient transferring to a different treatment facility or the outcome being 
unknown. 
• Treatment success: Treatment success is the sum of cure and treatment completion. 
 
In South Africa, the definitions of treatment outcomes used in the TB programme are similar 
to those provided by the WHO, with some minor differences, and are described in the National 
Tuberculosis Management Guidelines 2014 document (SA Department of Health, 2014). The 
definitions given by the WHO are for all bacteriologically confirmed and clinically diagnosed 
TB cases (WHO, 2014). On the other hand, those in the South African guidelines are split into 
2 groups: the first for patients with smear or culture positive pulmonary TB, and the second for 
patients with smear or culture negative pulmonary TB and patients with extra-pulmonary TB 
(SA Department of Health, 2014).  
 
The South African guidelines state that a cured patient should test smear or culture negative at 
least 30 days prior to the final test in the final month of treatment (SA Department of Health, 
2014), while the WHO does not state the amount of time required between the two tests (WHO, 
2014). In South Africa, patients who develop drug resistant TB during treatment should be 
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assigned the outcome ‘treatment failure’ (SA Department of Health, 2014), while the WHO 
states that when analysing treatment outcomes these patients should be included in the second-
line TB treatment analysis group instead of the main TB cohort (WHO, 2014).  
 
The South African guidelines define treatment default, which according to the definition used 
can only occur during treatment (SA Department of Health, 2014), whereas the WHO defines 
LTFU, which can occur before treatment begins or during treatment (WHO, 2014). The 
outcome ‘not evaluated’ is not included in the South African guidelines, but ‘transfer out’ is 
used instead (SA Department of Health, 2014). Transfer out is defined as “Patient who was 
referred to a facility in another district to continue treatment and for whom the treatment 
outcome is not known” (SA Department of Health, 2014). 
 
To help the country meet the WHO target of ending TB by 2035, South Africa has adopted the 
Stop TB’s Global Plan to End TB (Kigozi et al., 2017). The goals of the plan include reducing 
the total number of TB deaths by 90% and the incidence of TB by 80% by 2030 compared to 
2015 (WHO, 2016).  
 
1.2 Literature review 
Studies have found several factors that contribute to LTFU in TB patients (Garrido et al., 2012, 
Ifebunandu and Ukwaja, 2012, Kigozi et al., 2017, Shringarpure et al., 2015, Tola et al., 2015, 
Tupasi et al., 2016). In these studies, LTFU was defined as the interruption of TB treatment for 
at least two months. Factors influencing LTFU can be divided into four main groups: 
socioeconomic factors, other patient-related factors, treatment factors and health system or 
programmatic factors (SA Department of Health, 2014, Shringarpure et al., 2015). All the 
studies cited in this literature review involved both HIV-infected and uninfected TB patients, 
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except for the studies by Prado et al. (2017) and Satti and Kondagunta (2016) which involved 
HIV-infected TB patients only.  
 
While most of the studies were cohort studies, some authors used the case-control study design 
where age and sex were matched (Roy et al., 2015, Satti and Kondagunta, 2016), unmatched 
case-control study design (Culqui et al., 2012, Finlay et al., 2012, Hasker et al., 2008, Holtz et 
al., 2006, Tupasi et al., 2016), meta-analysis and systematic review (Toczek et al., 2013) and 
mixed methods (Chida et al., 2015, Sanchez-Padilla et al., 2014).  
 
In the review below, factors affecting LTFU outside South Africa are given first, then the 
factors influencing LTFU in South Africa are discussed. 
 
1.2.1 Socioeconomic factors 
Several studies have been conducted globally to determine the socioeconomic factors 
associated with LTFU. A lack of social support was found to be a predictor of LTFU, for 
example, if patients did not have somebody to go with them to the treatment clinic during the 
intensive treatment phase (Shringarpure et al., 2015, Tola et al., 2015). In one study, patients 
who experienced LTFU were likely to have small families, live alone and have a separated or 
disrupted marital status (Satti and Kondagunta, 2016). The presence of one or more of these 
factors may mean that a patient has reduced support and encouragement during TB treatment 
which may increase the risk of LTFU. These patients may also have lower levels of motivation 
during treatment. In many instances, the nature of TB treatment (the duration and the large 
number of drugs) is not consistent with a TB patient’s belief system, culture or living 
circumstances, so without an adequate support system, LTFU would probably occur (TB 
CARE I, 2014).  
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A lower socioeconomic level, unemployment, being a pensioner and the absence of transport 
money contributed to LTFU in TB patients (Hasker et al., 2008, Shringarpure et al., 2015). In 
settings where patients were responsible for paying for their treatment, the cost of TB treatment 
contributed to LTFU (Toczek et al., 2013). Although the cost of treatment for one TB patient 
in South Africa can be as high as US$26 392 (Pooran et al., 2013), TB diagnosis and treatment 
are provided free of charge in South Africa (Foster et al., 2015). Patients, however, still have 
many direct and indirect costs that average US$111.83 and US$212.24 respectively (Foster et 
al., 2015). The costs include nutritional supplements, transport and carer costs (Foster et al., 
2015). These costs may influence unemployed TB patients or those with a lower SES to 
discontinue TB treatment.  
 
Shringarpure et al. (2015) found that the lower the level of education attained by a patient, the 
more likely the patient is to be lost to follow-up. Akessa et al. (2015) found that living in a 
rural area and a change of residence during treatment were associated with LTFU. A study by 
Tupasi et al. (2016) found that residence in an urban slum significantly increased LTFU. This 
may be due to the difficult socioeconomic conditions, such as inadequate housing and limited 
access to healthcare and other services, found in slums (Kizito et al., 2011). The mobile nature 
of the population, likely fuelled by the poor living conditions, may also exacerbate LTFU 
(Kizito et al., 2011).  
 
Socioeconomic factors influencing LTFU in South Africa include living in rural areas, not 
owning a radio, being born outside of South Africa, migration and not having time to go to the 
treatment clinic (Holtz et al., 2006). Immigrants have been found to struggle to understand the 
treatment, increasing the likelihood of LTFU (Caylà et al., 2009). In addition, LTFU among 
migrants may occur due to fear of deportation, anti-migrant sentiments, low incomes, lack of 
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access to care and information (IOM, 2013, IOM, 2014). South Africa has a high number of 
migrants, both internal and external, and this may drive LTFU. Ekurhuleni may be a popular 
district for migrants to settle in on arrival in Gauteng due to a lower cost of living in the district.  
 
One study found that TB patients with a formal salary had higher rates of LTFU than patients 
that relied on family and social contributions (Peltzer and Louw, 2014). This may be due to the 
fact that employment has been found to influence LTFU for many reasons, including patients 
not wanting their co-workers to know that they were ill and employers not allowing patients 
time off or paid sick leave (Finlay et al., 2012). A lack of formal education, working as a 
labourer and taking treatment without eating (due to a lack of food) increased the risk of LTFU 
(Finlay et al., 2012).  
 
1.2.2 Other patient-related factors 
Many studies conducted worldwide have investigated the effects of patient-related factors on 
LTFU during TB treatment. Using tobacco during TB treatment was significantly associated 
with LTFU (Dooley et al., 2011, Kuchukhidze et al., 2014). While some authors have found 
that LTFU is more likely to occur in men and in older patients (Ifebunandu and Ukwaja, 2012, 
Sanchez-Padilla et al., 2014), others found that a patient’s sex and age have no influence on 
LTFU (Akessa et al., 2015, Kuchukhidze et al., 2014). A study in Brazil found that black TB 
patients were more likely to experience LTFU than any other race (Prado et al., 2017).  
 
Incarceration, whether previous or current, was found to influence LTFU during TB treatment 
(Kuchukhidze et al., 2014, Sanchez-Padilla et al., 2014). Kuchukhidze et al. (2014) did not find 
BMI to be associated with LTFU, whereas Shringapure et al. (2015) found that patients with a 
low BMI were most likely to experience LTFU. A low BMI can be an indicator of other factors 
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that may influence LTFU such as a low socioeconomic status, inadequate access to healthcare 
and co-morbidities.  
 
A low general knowledge about TB increased the likelihood of LTFU (Tupasi et al., 2016). 
Patients who were lost to follow-up were found to not know the duration of treatment (Putera 
et al., 2015). Pre-existing pulmonary disease (Garrido et al., 2012) and psychiatric disorders 
(Toczek et al., 2013) were found to increase the risk of LTFU. In addition, community beliefs 
were found to influence LTFU (Ade et al., 2016), for example, some communities believed 
that TB treatment would make them sterile (Chida et al., 2015). HIV testing was found to be 
protective against LTFU (Lackey et al., 2015). 
 
In South Africa, a study found that older patients were more likely to be lost to follow-up than 
younger ones (Gafar et al., 2014). Smoking marijuana and mandrax during TB treatment, as 
well as spending time in prison had a negative effect on LTFU in TB patients (Holtz et al., 
2006). A study found that the use of illicit drugs has been increasing in Gauteng (Mushayabasa 
and Tapedzesa, 2015). Drugs may influence TB patients to make poor decisions, which may 
lead to LTFU. The combination of the illicit drugs and TB medication may also worsen side 
effects of medications and force patients to abandon care. Feeling ashamed of the TB diagnosis 
and visiting a traditional healer were found to significantly increase LTFU (Finlay et al., 2012). 
Patients with an unknown HIV status were 30% more likely to be lost to follow-up than patients 
who were HIV-uninfected (Kigozi et al., 2017). 
 
1.2.3 Treatment factors 
Hasker et al. (2008), Ifebunanda and Okwaja (2012) and Roy et al. (2015) found that most 
patients who were lost to follow up were lost to follow-up during the intensive phase of TB 
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treatment. On the other hand, Akessa et al. (2015) and Kuchukhidze et al. (2014) found that 
most patients who were lost to follow up were lost to follow-up in the continuation phase. Side 
effects from the medication were reported as a common cause of LTFU (Hasker et al., 2008, 
Roy et al., 2015, Shringarpure et al., 2015, Tola et al., 2015). Side effects due to TB treatment 
include nausea, joint pain, abdominal cramps, dizziness, peripheral neuropathy, and 
hepatotoxicity (Arbex et al., 2010).  
 
Kuchukhidze et al. (2014) observed that previous treatment was significantly associated with 
LTFU while Sanchez-Padilla et al. (2014) and Akessa et al. (2015) did not find a significant 
association. Tola et al. (2015) found that the likelihood of LTFU increased if symptoms 
decreased. Pulmonary TB, culture conversion, smear status, the drug-resistance status of the 
bacteria and the number of treatment interruptions were found to be significantly associated 
with LTFU (Kuchukhidze et al., 2014, Sanchez-Padilla et al., 2014). Patients receiving 
treatment for MDR-TB were more likely to be lost to follow-up than those with drug-sensitive 
TB (Lackey et al., 2015). In India, missing 5 or more treatment doses increased the risk of 
LTFU (Roy et al., 2015).  
 
In South Africa patients were more likely to be lost to follow-up if the treatment did not relieve 
their symptoms (Holtz et al., 2006, Finlay et al., 2012). Patients who had a history of LTFU 
from treatment had a higher likelihood of LTFU (Gafar et al., 2014).  
 
1.2.4 Health system or programmatic factors 
The literature is clear that the relationship between a patient and the healthcare provider is 
important in preventing LTFU during TB treatment. Patients who did not have a good 
relationship with the health care workers at the treatment centres were more likely to be lost to 
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follow-up (Roy et al., 2015, Tola et al., 2015). Common problems encountered were patients 
not being happy about the healthcare worker’s attitude towards them, a lack of trust in and 
support from the health care workers, and poor communication (Tola et al., 2015, Tupasi et al., 
2016). Patients who received little assistance from the health facility during treatment had a 
high likelihood of LTFU (Tupasi et al., 2016).  
 
An association between increased rates of LTFU and large programme sizes and drug stock-
outs was found (Toczek et al., 2013). Standardising treatment regimens and providing financial 
and nutritional support to patients resulted in a reduction in LTFU, but the use of legal action 
to force patients to adhere to treatment did not make a difference (Toczek et al., 2013). Patients 
were more likely to be lost to follow-up if they received treatment at a government treatment 
facility than patients who received treatment at a community facility (Roy et al., 2015). Private 
treatment facilities were also found to be protective against LTFU (Sitienei et al., 2015). Long 
waiting times, the need for repeated visits and delays in obtaining test results resulted in 
increased rates of LTFU (MacPherson et al., 2014). 
 
In South Africa, healthcare system factors associated with LTFU include long waiting periods 
for culture test results and delayed treatment initiation (Padayatchi et al., 2014). Drug stock-
outs and shortages have also been implicated in treatment LTFU (Padayatchi et al., 2014, 
Seunanden and Day, 2014). Poor relationships with healthcare workers contributed to LTFU 
(Holtz et al., 2006). Insufficient education on TB treatment, not being told that treatment lasts 
at least 6 months and feeling as though the provision of food by healthcare workers during TB 
treatment would help the patient finish their treatment contributed to patients not adhering to 
TB treatment (Finlay et al., 2012).  
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Treatment in community healthcare centres was found to influence LTFU (Gafar et al., 2014). 
In general, the inadequate number of healthcare professionals and an overburdened healthcare 
system in South Africa have contributed to LTFU during TB treatment as the standard of care 
has been reduced by these factors (Finlay et al., 2012). Poor follow-up systems and 
mismanaged treatment programmes have been found to influence LTFU (Kigozi et al., 2017). 
Finlay et al. (2012), found that DOTS did not make a difference to LTFU rates as half of the 
patients on DOTS reported that they did not take their medication under direct supervision. The 
lack of supervision may be caused by the shortage of healthcare workers or by unmotivated 
healthcare workers due to the state of the healthcare system. Inconvenient clinic hours were 
also associated with increased LTFU during TB treatment (Finlay et al., 2012). 
 
1.3 Problem statement 
A search of the literature shows that most work that has been done to determine the factors 
influencing LTFU in South Africa has been done in HIV/TB co-infected patients. 
Approximately 57% of TB patients in South Africa are infected with HIV (Massyn et al., 2016). 
As a result, there is a knowledge gap of the factors influencing LTFU in the remaining 43% of 
TB patients who are HIV-uninfected. 
 
The patterns of TB disease are different in HIV-infected and HIV-uninfected patients, for 
example, HIV-infected patients are more likely to have EPTB (Fenner et al., 2012, 
Gebremariam et al., 2016) and acid-fast smear-negative TB (Sterling et al., 2010). Acid-fast 
smear-negative TB is active TB that gives a negative result when a smear test is done using a 
rapid test. Furthermore, HIV-infected TB patients have a high pill burden and drug interactions 
(Sterling et al., 2010). Death during TB treatment is more common in HIV-infected patients 
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than in HIV-uninfected patients (Mohr et al., 2015). Side effects, however, have been found to 
be similar in both HIV-infected and uninfected TB patients (Shean et al., 2013).  
 
The differences in the patterns of TB disease mentioned above are likely to influence 
differences in patterns of LTFU between the two groups. Studies to determine the factors 
influencing LTFU in HIV-uninfected TB patients are required as very few have been conducted 
in South Africa. In addition, no studies that focused on ‘outcome not evaluated’ were found 
during the literature search.  
 
1.4 Justification  
Knowledge of the factors that influence LTFU during TB treatment is important as patients 
who are lost to follow-up have a high risk of spreading the infection to their contacts, 
developing drug resistant TB and dying (Akessa et al., 2015, Kuchukhidze et al., 2014). A 
study conducted in Peru found that about 50% of patients who were lost to follow-up during 
TB treatment did not survive for more than 3 years after LTFU (Toczek et al., 2013). In Brazil, 
the death rate among patients who were lost to follow-up was 4.2 times higher than the death 
rate in patients who were not lost to follow-up (Cunha et al., 2017). Patients who were lost to 
follow-up early-on had a higher risk of death than those that were not (Cunha et al., 2017). The 
financial burden on the healthcare system is increased when adherence to TB medication is low 
(Lackey et al., 2015).   
 
Patients who transfer out during TB treatment and whose outcome is unknown by the sending 
clinic are normally assigned the outcome ‘treatment not evaluated’ (Takarinda et al., 2012). 
These patients can be considered to be lost to follow-up. Transfer during TB treatment has been 
linked to a reduction in treatment compliance which increases the risk of LTFU (Belayneh et 
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al., 2016). The results obtained in this study will help inform interventions and efforts to reduce 
LTFU in HIV-uninfected TB patients in South Africa. 
 
1.5 Study Question 
What demographic and clinical factors are associated with LTFU during TB treatment among 
HIV-uninfected TB patients from Ekurhuleni North sub-district who registered for TB 
treatment from 1st January 2011 to 30th June 2012? LTFU was defined as a lack of a 
documented treatment outcome among TB patients who should have completed TB treatment 
based on TB treatment start date. Patients who were lost to follow-up and interrupted treatment 
(previously described as default) and those who were lost to follow-up but not successfully 
traced (outcome not evaluated) were assigned the outcome LTFU. Since there were no records 
of any participants transferring out during TB treatment, no study participants were assigned 
the outcome LTFU based on transfer out. 
 
1.6 Aim  
To determine the demographic and clinical factors associated with LTFU in HIV-uninfected 
TB patients who registered for TB treatment in Ekurhuleni North sub-district from 1st January 
2011 to 30th June 2012. The patients were followed up until the end of treatment or until data 
were collected from November 2012 to June 2013. 
 
1.7 Objectives 
1. To describe the clinical and demographic characteristics of HIV-uninfected TB patients 
who registered for TB treatment in Ekurhuleni North sub-district from 1st January 2011 
to 30th June 2012. 
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2. To determine the burden of LTFU among HIV-uninfected TB patients who registered 
for TB treatment in Ekurhuleni North sub-district from 1st January 2011 to 30th June 
2012.  
3. To determine the clinical and demographic factors associated with LTFU in HIV-
uninfected TB patients who registered for TB treatment in Ekurhuleni North sub-
district from 1st January 2011 to 30th June 2012.  
4. To determine if there is a difference in time to LTFU among HIV-uninfected TB 
patients who registered for TB treatment in Ekurhuleni North sub-district from 1st 
January 2011 to 30th June 2012 based on clinical and demographic factors. 
  
16 
 
CHAPTER 2: METHODS 
This chapter presents the materials and methods used in this study. The study design, study 
population, study site, primary study, sampling method, data cleaning, variables used and data 
analysis are described here. 
 
2.1 Study design 
This study was a retrospective cohort study. The study involved secondary data analysis of data 
collected during a study entitled “Evaluation of the detection, management and outcomes of 
TB and TB treatment outcomes at 18 primary care facilities in Ekurhuleni North sub-district.”  
 
2.2 The primary study 
The primary study was a retrospective cohort study based on record review and abstraction. 
The study was conducted at 18 primary care clinics in Ekurhuleni North sub-district. The 
overall objective of the study was to evaluate case detection, management and treatment 
outcomes among HIV-infected and uninfected TB patients who registered for TB treatment at 
the clinics during the period 1st January 2011 to 30th June 2012. The clinics were selected for 
the study from a total of 32 primary care clinics in Ekurhuleni North because they offered TB 
diagnosis and treatment services, had no other research activities and had sufficient numbers 
of patients for the study.  
 
Data were collected from the TB treatment registers and other clinic records such as clinic 
cards and the antiretroviral therapy (ART) register. Demographic variables, TB diagnostic 
methods variables and TB treatment and management variables were collected. The data 
collected had been compiled over the duration of TB treatment as participants went to the 
treatment clinics for regular appointments. Record review and abstraction (data collection for 
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the primary study) began in November 2012 and ended in June 2013. In total, 2 971 patients 
were enrolled in the primary study. The results of the study were used to assist with the planning 
of a TB/HIV integration project as well as TB treatment and vaccine trials in Ekurhuleni North 
sub-district. 
 
2.3 Study site 
The study site comprised 18 clinics offering primary health care in Ekurhuleni North sub-
district. Ekurhuleni North sub-district is located in the Ekurhuleni Metropolitan Municipality, 
Gauteng Province, South Africa (Statistics South Africa, 2016). In 2016, Ekurhuleni had a 
population of 3.2 million people (Statistics South Africa, 2016). The TB treatment success rate 
was 87.2% in 2012 (Massyn et al., 2014). In 2015, there were 298 incident cases of TB per 
100 000 population in Ekurhuleni, with a treatment success rate of 85.6%, and a death rate of 
5.6% (Massyn et al., 2016). Between 2009 and 2014, TB was the most common cause of death 
among 15-64 year olds in Ekurhuleni (Massyn et al., 2016). Sixty-eight percent of TB patients 
in Ekurhuleni were HIV positive in 2015 (Massyn et al., 2016).  
 
2.4 Study population 
The study population consisted of 515 HIV-uninfected TB patients who registered for TB 
treatment in Ekurhuleni North sub-district between 1st January 2011 and 30th June 2012. 
Participants should have completed TB treatment based on TB treatment start date by the time 
the data were collected for the primary study to be included in the study. All study participants 
were adults aged 18 years and above at the start of TB treatment. No patients with drug resistant 
TB were included in the study as treatment for drug resistant TB was not provided at the clinics 
during the treatment registration period. 
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2.5 Sampling 
A sub-sample of the original data was selected by excluding the HIV-infected patients in the 
study. The StatCalc command in EpiInfo 7 was used to calculate the sample size. The sample 
size required for this study was 59 and 88 at the 80% and 90% power levels respectively. With 
515 HIV-uninfected participants in the study, the dataset was large enough for the study. The 
assumptions made were that, on average, 11% of patients are lost to follow-up during TB 
treatment in Johannesburg (Budgell et al., 2016), the acceptable margin of error was 5% and 
the design effect was 1. 
 
2.6 Methods for measuring outcomes 
The main outcome was LTFU. Patients whose treatment outcomes in the primary study were 
recorded as default or unknown/no record or were missing were considered lost to follow-up. 
The participants with the remaining treatment outcomes (cured, treatment completed, MDR-
TB, died and failure) were considered to not be lost to follow-up. 
 
The length of treatment was calculated as follows: date of treatment completion minus date of 
treatment commencement for patients who completed TB treatment, and date of most recent 
clinic visit minus date of treatment commencement for patients who were either lost follow-up 
or died during treatment. The length of treatment was calculated in months.  
 
A participant was said to change treatment phase when he/she went from the intensive phase 
to the continuation phase. Time to change of treatment phase was calculated by subtracting the 
date treatment began from the date of change of treatment phase. The time to change of 
treatment phase was calculated in months. 
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2.7 Data management and analysis 
2.7.1 Data cleaning 
The software used in this study was STATA 14. The dataset had 2 971 participants, composed 
of HIV-infected and uninfected participants. Participants who had missing, positive or 
unknown HIV results were excluded from the study. Some of the records were duplicated. The 
observations that were kept in the study were the ones with the outcome recorded. Where both 
observations had an outcome, the latest recorded observation was kept. Participants who were 
still receiving treatment when the data were collected were excluded from the study. The final 
number of participants in the study was 515.  
 
 
Figure 2.1: Flow chart showing participant eligibility criteria  
 
The variables used in the study is described in Table 2.1 below. The coding used for all the 
variables used in the project is given in the Appendix in Table A1. 
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Table 2.1: Description of the variables used in the study 
Variable Description 
Participant ID The participant IDs in the primary study were in the form ‘Protocol-Site 
code-Participant ID’. Unique, numerical identification numbers were 
assigned to all participants to increase the ease of data cleaning. 
Treatment clinic The treatment clinic was obtained from the participant IDs given in the 
primary study.  
Age at TB 
diagnosis 
Categorised into 18-34 years and 35+ years. The median age of the 
participants was 33 years, so the two age categories were created based 
on this value while ensuring that participants were relatively equally 
distributed between the two.  
Patient burden 
at treatment 
clinic 
The clinics were classified as having a low or high patient burden 
depending on the number of HIV-uninfected TB patients treated. 
Clinics that had 40 or more HIV-uninfected TB patients were classified 
as having a high patient burden. 
TB treatment 
outcome 
This variable was created to take into account the definition of LTFU 
used in this study. Participants with unknown/missing and default as 
treatment outcomes in the primary study were assigned LTFU as their 
outcome in this study. Participants who had a missing outcome were 
also assigned LTFU as their treatment outcome. The treatment 
outcomes in the new treatment outcome variable were treatment success 
(which was the sum of cured and completion), LTFU, MDR-TB, death 
and treatment failure. There was no information on patient transfer 
during treatment. 
Success or poor 
treatment 
outcome 
Treatment outcomes were classified as success or poor outcomes. 
Successful treatment outcomes were cured and completion. Poor 
treatment outcomes were LTFU, MDR-TB, death and treatment failure. 
Date variables New date variables in STATA format were created. These variables 
were treatment start date, date of change of treatment phase, date of 
most recent clinic visit and date of treatment completion. 
Date of 
treatment exit 
For participants who were either lost to follow-up or had died, the exit 
date was the date of the most recent clinic visit. The date of completion 
of TB treatment was the exit date for participants who completed TB 
treatment. 
Time to LTFU The time to LTFU was calculated in months using the date of most 
recent clinic visit minus the date treatment began. 
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2.7.2 Data analysis 
The purpose of this section is to describe the statistical analysis methods used to complete 
each objective.  
 
• Objective 1: To describe the clinical and demographic characteristics of HIV-
uninfected TB patients. 
The variables were divided into two groups: demographic and clinical variables at the start of 
TB treatment and variables describing TB treatment duration and outcomes. The variables used 
to describe the participants at the start of treatment were age at TB diagnosis, sex, episode type, 
TB site, smear and culture status and patient burden at treatment clinic. Age was used in its 
continuous and categorical forms while the remaining variables were categorical. The 
continuous variables used to describe the treatment duration and outcomes were length of 
treatment, time to LTFU and time to change of treatment phase. The categorical variables were 
change of treatment phase, treatment outcome, LTFU, length of treatment, time to LTFU and 
time to change of treatment phase.  
 
The median and interquartile range (IQR) were calculated for the continuous variables. 
Proportions were calculated for the categorical variables. Treatment outcome by treatment 
clinic and by patient burden at treatment clinic were determined. The treatment outcomes were 
grouped into success and poor outcomes for these analyses. 
 
• Objective 2: To determine the burden of LTFU among HIV-uninfected TB patients. 
The outcome variable was LTFU. The variables used were age at TB diagnosis, length of 
treatment, time to change of treatment phase, sex, episode type, change of treatment phase, 
patient burden at treatment clinic and TB site, smear and culture status. The proportion of 
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participants with LTFU was determined for each independent variable. The median and IQR 
were calculated for each category (except unknown/missing) for age at TB diagnosis, length of 
treatment and time to change of treatment phase. The proportions and p-values were calculated 
for the categorical variables. The chi-squared test, conducted at the 5% significance level, was 
used to calculate the p-values.  
 
• Objective 3: To determine the clinical and demographic factors associated with LTFU 
in HIV-uninfected TB patients 
The outcome variable was LTFU. The variables used were age at TB diagnosis, sex, episode 
type, patient burden at treatment clinic and TB site, smear and culture status (all categorical). 
Logistic regression modelling was used as the outcome was binary. Univariate analysis was 
conducted to test the association between each factor and LTFU. The p-values, odds ratios and 
95% confidence intervals (CI) were obtained.  
 
For multivariate analysis, multiple logistic regression modelling was used. A p-value cut-off 
of 0.2 was used to select variables for multivariate analysis. Age and sex were included a priori. 
The p-values, odds ratios and 95% CI were obtained. Confounding and interaction were 
investigated. To be considered a confounder, a variable needed to change the odds ratio of 
another variable by 10% after adjusting for it. The likelihood ratio test was used to test if 
interactions improved the model obtained. A test of goodness of fit was conducted to test the 
goodness of fit of the model obtained. For both univariate and multivariate analysis, the level 
of statistical significance was 5%. 
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• Objective 4: To determine if there is a difference in time to LTFU among HIV-
uninfected TB patients based on clinical and demographic factors 
The date variables used were treatment start date and exit date. The categorical variables were 
age at LTFU, age at TB diagnosis, sex, episode type, TB site, smear and culture status, and 
patient burden at treatment clinic. The failure event was LTFU. The origin was the date that 
TB treatment began, and participants would exit on or before the failure event.  
 
The Kaplan-Meier method was used for survival analysis. The number of events (LTFU), 
incidence rate, 95% CI and p-value were obtained. The incidence rate was obtained per 100 
person-months as the length of TB treatment was in months. The log-rank test was used to test 
for a statistically significant association between the variables and time to LTFU at a 5% 
significance level. A graph of the Kaplan-Meier failure estimate was generated. 
 
Cox proportional hazards regression was used identify factors associated with LTFU. 
Univariate and multivariate analyses were conducted. Factors that had been used in 
multivariate logistic regression were used for the multivariate Cox proportional hazards 
regression, regardless of the p-value in univariate analysis. Confounding and interaction were 
investigated, and a test of proportional hazards assumption was conducted. 
 
2.8 Sensitivity analyses 
Analyses 1 and 2 
Sensitivity analyses were conducted to determine if censoring participants after eight months 
of treatment had any effect on the results of the multivariate logistic regression and Cox 
proportional hazards regression analyses. The data were censored at eight months because TB 
treatment normally lasts six to eight months.   
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Analysis 3 
Sensitivity analysis was also conducted around the definition of LTFU. Multivariable logistic 
regression analysis was conducted where participants with a missing outcome were assumed 
to have been followed up elsewhere, so that only the participants with default as an outcome in 
the primary study were considered to be lost to follow-up in this study.  
 
2.9 Ethics 
The primary study received ethics clearance from the Human Research Ethics Committee 
(HREC) (Medical) at the University of the Witwatersrand (certificate number M120830). For 
this study, permission to use the data was obtained from the Aurum Institute. Ethics clearance 
was obtained from HREC (Medical) at the University of the Witwatersrand (certificate number 
M161183).   
25 
 
CHAPTER 3: RESULTS 
This chapter will present the results obtained during this study. In total, 515 participants were 
eligible for the study. The demographic and clinical characteristics of the participants and the 
burden of LTFU are described. The results of the logistic regression, time to event analysis, 
Cox proportional hazards regression and sensitivity analyses are also presented.     
 
3.1 Description of the clinical and demographic characteristics of the study participants 
Table 3.1 presents the results of the descriptive analysis of the participants’ demographic and 
clinical data at the start of TB treatment. The median age at TB diagnosis was 33 years (IQR: 
26-47). Just over half of the participants (53.40%) were aged between 18 and 34 years. The 
majority of the participants (58.09%) were male. More than 90% of the participants had a new 
TB episode. Almost 48% of the participants had pulmonary TB that was smear or culture 
positive. There was a fairly even distribution of the remaining participants between pulmonary 
smear and culture negative TB, and non-pulmonary TB. More participants were treated at 
clinics that had a low patient burden (less than 40 HIV-uninfected TB patients) than at clinics 
that had a high patient burden. Five of the 18 clinics had a high patient burden. 
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Table 3.1: Demographic and clinical characteristics of the study participants at the start 
of TB treatment 
Variable Median (IQR) 
Age at TB diagnosis (years) 33 (26-47) 
Variable N (%) 
Age at TB diagnosis (years) 
18-34 275 (53.40) 
35+ 240 (46.60) 
Sex 
Male 298 (58.09) 
Female 215 (41.91) 
Episode type 
New 479 (93.19) 
Re-treatment 35 (6.81) 
TB site, smear and culture status 
Pulmonary smear or culture positive 246 (47.77) 
Pulmonary smear and culture negative 131 (25.44) 
Non-pulmonary 138 (26.80) 
Patient burden at treatment clinic 
Low burden (n=13) 274 (53.31) 
High burden (n=5) 240 (46.69) 
 
Table 3.2 shows the summary of the TB treatment duration and outcomes. The median length 
of treatment was 6.39 months (IQR 5.67-7.44). The median time to LTFU was 3.67 months 
(IQR 1.54-6.33), which would be during the continuation phase. The majority of patients 
(82.33%) changed treatment phase at some point during treatment. The median time to change 
of treatment phase was 2.36 months (IQR 2.03-3.02).    
 
The majority of the participants were on TB treatment for six to nine months. LTFU was 
highest in the first two months of treatment (26.97%), and lowest four to six months into 
treatment (16.85%). Change of treatment phase was highest two to four months after the start 
of treatment (74.53%). 
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Four hundred participants (77.67%) had a successful treatment outcome. Of these, 297 
(56.67%) were cured, and 103 (20%) completed TB treatment (results not shown). Two 
participants (0.39%) experienced treatment failure and 24 participants (4.66%) died during 
treatment. Eighty-nine participants (17.28%) were lost to follow-up. Of these, 29 participants 
had default as their treatment outcome and 60 participants had a missing treatment outcome. 
 
Table 3.2: Description of TB treatment duration and outcomes 
Variable Median (IQR) 
Length of treatment (months) 6.39 (5.67-7.44) 
Time to LTFU (months) 3.67 (1.54-6.33) 
Time to change of treatment phase 
(months) 
2.36 (2.03-3.02) 
Variable N (%) 
Change of treatment phase 
No  47 (9.13) 
Yes 424 (82.33) 
Unknown/missing 44 (8.54) 
TB treatment outcome 
Success 400 (77.67) 
LTFU 89 (17.28) 
Died 24 (4.66) 
Treatment failure 2 (0.39) 
Loss to follow-up 
No LTFU 426 (82.72) 
LTFU 89 (17.28) 
Length of treatment (months) 
Less than 6 149 (28.93) 
6-9 283 (54.95) 
9-12  39 (7.57) 
Unknown/missing 44 (8.54) 
Time to LTFU (months) 
Less than 2  24 (26.97) 
2-4 17 (19.10) 
4-6 15 (16.85) 
6-12 23 (25.84) 
Unknown/missing 10 (11.24) 
Time to change of treatment phase (months) 
Less than 2 56 (13.21) 
2-4 316 (74.53) 
4-6 17 (4.01) 
6-12 3 (0.71) 
Unknown/missing 32 (7.55) 
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Figure 3.1 shows the distribution of treatment outcome by treatment clinic. LTFU, death and 
treatment failure were categorised as poor treatment outcomes. At all clinics, the majority of 
participants had a successful treatment outcome. The most common poor outcome was LTFU, 
which was observed at all but two clinics. Seventy-seven percent of the poor outcomes were 
LTFU. 
 
Clinics J, A and R had success rates greater than 90%. Clinics Q, H and B had the lowest TB 
treatment success rates of 63%, 64% and 65% respectively. No poor treatment outcomes were 
observed at Clinics K and O. Clinics Q, H and B had the highest proportions of poor outcomes 
(38%, 36% and 35% respectively). At Clinic Q, the only poor outcome recorded was LTFU. 
Treatment failure was recorded at Clinics G and M.  
 
 
Figure 3.1: TB treatment outcome by treatment clinic. Poor outcomes consisted of LTFU 
(17.12%), died (4.67%) and treatment failure (0.39%). The total number of participants at each 
treatment clinic is shown. One participant was excluded from this analysis as information on 
the treatment clinic attended was not available. 
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Figure 3.2 shows treatment outcome by the patient burden at the treatment clinics. Almost 
equal proportions of treatment success and poor outcomes were observed in low and high 
patient burden treatment clinics. In the clinics with a low patient burden, 22% of participants 
had a poor treatment outcome while 23% had a poor treatment outcome in the high patient 
burden clinics. 
 
 
Figure 3.2: TB treatment outcome by patient burden at treatment clinic. Poor outcomes 
consisted of LTFU (17.12%), died (4.67%) and treatment failure (0.39%). One participant was 
excluded from this analysis as information on the treatment clinic was not available. No 
statistically significant difference in levels of poor outcomes was observed between low and 
high patient burden clinics. 
 
3.2 Burden of LTFU among study participants 
Table 3.3 shows the results of the comparison of demographic and clinical characteristics 
among those who were lost to follow-up and those who were not lost to follow-up. The p-value 
shown is for the categorical variables.  
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An overwhelmingly significant difference in the median length of treatment was found between 
participants who were lost to follow-up and participants who were not lost to follow-up. Most 
LTFU occurred in the first six months of treatment, and as expected, these participants had a 
lower median duration of treatment than participants who were not lost to follow-up. 
Participants who were lost to follow-up may not have been on TB treatment long enough to 
change treatment phase, resulting in a significant difference in LTFU being observed among 
participants who changed treatment phase and those who did not change treatment phase.  
 
The difference in the time to change of treatment phase between the two groups was not 
statistically significant. With the exception of participants who changed treatment phase 
between two and twelve months after treatment commencement, participants who were lost to 
follow-up had a lower median time to change of treatment phase compared to participants who 
were not lost to follow-up. No participants were lost to follow-up four to six months after 
treatment began. Those who were lost to follow-up had the same median age as those who were 
not lost to follow-up for both age categories. No significant differences in age, sex, episode 
type, patient burden at treatment site and TB site, smear and culture status were observed 
among those who were lost to follow-up and those who were not lost to follow-up.  
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Table 3.3: Burden of LTFU among HIV-uninfected TB patients by selected 
demographic and clinical characteristics 
Variable No LTFU [n (%)] LTFU [n (%)] p-value 
Age at TB diagnosis (years) 0.201 
18-34 
Median (IQR) 
222 (80.73) 
26 (23-30) 
53 (19.27) 
26 (24-29) 
35+ 
Median (IQR) 
204 (85.00) 
48 (42-55) 
36 (15.00) 
48 (40-57) 
Length of treatment (months) < 0.001 
Less than 6 
Median (IQR) 
93 (62.42) 
5.34 (3.90-5.77) 
56 (37.58) 
2.31 (0.97-4.11) 
6-9  
Median (IQR) 
265 (93.64) 
6.69 (6.26-7.61) 
18 (6.36) 
7.13 (6.72-7.38) 
9-12  
Median (IQR) 
34 (87.18) 
9.55 (9.18-10.10) 
5 (12.82) 
9.80 (9.70-10.30) 
Unknown/missing 34 (77.27) 10 (22.73) 
Time to change of treatment phase (months) 0.375 
Less than 2 
Median (IQR) 
51 (91.07) 
1.84 (1.64-1.93) 
5 (8.93) 
1.77 (1.64-1.97) 
2-4 
Median (IQR) 
287 (90.82) 
2.46 (2.10-2.98) 
29 (9.18) 
2.98 (2.30-3.18) 
4-6  
Median (IQR) 
17 (100.00) 
4.56 (4.16-4.89) 
0 (0.00) 
- 
6-12  
Median (IQR) 
2 (66.67) 
6.95 (6.26-7.64) 
1 (33.33) 
7.08 (7.08-7.08) 
Unknown/missing 30 (93.75) 2 (6.25) 
Sex 0.759 
Male 245 (82.21) 53 (17.79) 
Female 179 (83.26) 36 (16.74) 
Episode type 0.369 
New 398 (83.09) 81 (16.91) 
Re-treatment 27 (77.14) 8 (22.86) 
TB site, smear and culture status* 0.605 
A 202 (82.11) 44 (17.89) 
B 112 (85.50) 19 (14.50) 
C 112 (81.16) 26 (18.84) 
Change of treatment phase <0.001 
No 22 (46.81) 25 (53.19) 
Yes 387 (91.27) 37 (8.73) 
Unknown/missing 17 (38.64) 27 (61.36) 
Patient burden at treatment clinic 0.624 
Low burden 225 (82.12) 49 (17.88) 
High burden 201 (83.75) 39 (16.25) 
* A: Pulmonary smear or culture positive; B: Pulmonary smear and culture negative; C: Non-
pulmonary 
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3.3 Factors associated with LTFU 
Table 3.4 shows the results of the univariate logistic regression analysis used to determine the 
factors associated with LTFU during TB treatment in HIV-uninfected TB patients. No factor 
was found to be significantly associated with LTFU during TB treatment. Participants aged 35 
years and above had a 26% lower risk of LTFU than participants aged 18-34 years. Female 
participants were 7% less likely to be lost to follow-up compared to men. Participants with 
smear and culture negative pulmonary TB had 22% lower risk of LTFU compared to 
participants with smear or culture positive pulmonary TB. Participants with non-pulmonary 
TB had a 7% higher risk of LTFU than participants with smear or culture positive pulmonary 
TB. Participants who received TB treatment at clinics with a high patient burden had an 11% 
lower risk of LTFU than participants treated a clinic with a low patient burden. 
 
Table 3.4: Results of the univariate logistic regression to determine factors associated 
with LTFU 
Factor Odds ratio 95% CI p-value 
Age at TB diagnosis  
18-34 1 (base) 
35+ 0.74 0.46-1.18 0.202 
Sex  
Male  1 (base) 
Female 0.93 0.58-1.48 0.759 
Episode type  
New 1 (base)   
Re-treatment 1.46 0.64-3.32 0.372 
TB site, smear and culture status *  
A 1 (base) 
B 0.78 0.43-1.40 0.403 
C 1.07 0.62-1.82 0.816 
Patient burden at treatment clinic  
Low  1 (base) 
High 0.89 0.56-1.41 0.624 
* A: Pulmonary smear or culture positive; B: Pulmonary smear and culture negative; C: Non-
pulmonary 
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Table 3.5 shows the results of the multivariate logistic regression analysis. Age at TB diagnosis 
and sex were the variables included in the multivariate analysis. No statistically significant 
association between age at TB diagnosis, sex and LTFU was found. Participants aged 35 years 
and above were 27% less likely to be lost to follow-up than participants aged 18-34 years. 
Female participants had a lower risk of LTFU (OR 0.89, 95% CI 0.55-1.42; p = 0.620) than 
male participants. No confounding or interaction between the variables was observed. 
Goodness of fit of the model was observed (p = 0.472). 
 
Table 3.5: Results of multivariate logistic regression to determine the factors associated 
with LTFU (N = 513) 
Factor Adjusted odds ratio 95% CI p-value 
Age at TB diagnosis 
18-34 1 (base) 
35+ 0.73 0.45-1.16 0.183 
Sex 
Male 1 (base) 
Female 0.89 0.55-1.42 0.620 
 
3.4 Survival analysis 
Data from 469 participants were used in the survival analysis due to missing or incorrect dates. 
Seventy-five participants had the outcome of interest (LTFU) during the 12-month follow-up. 
The incidence rate of LTFU among the study participants was 2.51 (95% CI 2.00-3.15) per 100 
person-months. The total person-time of follow-up was 2 985 months. 
 
Figure 3.3 shows the Kaplan-Meier failure curve. The graph shows the probability of LTFU 
over 12 months of follow-up. The probability of LTFU was found to increase with increasing 
time. During the first six months of follow up the increase was at a constant rate. The 
probability of LTFU was 4% after two months and 12% at six months.  
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Figure 3.3: Probability of LTFU over 12 months of follow-up 
 
Table 3.6 shows the results of the survival analysis. No statistically significant differences in 
survival functions between the different categories were observed for all of the tested variables. 
Participants aged 18-34 years had a higher incidence rate of LTFU (2.79 per 100 person-
months; 95% CI: 2.08-3.75) than participants aged 35 years and above (2.20 per 100 person-
months; 95% CI: 1.55-3.13). Male participants had a slightly higher incidence rate of LTFU 
(2.55 per 100 person-months; 95% CI: 1.90-3.41) than female participants (2.49 per 100 
person-months; 95% CI: 1.74-3.56).  
 
Participants with a new TB episode had a slightly lower incidence rate of LTFU than 
participants who had a retreatment episode of TB. The incidence rate of LTFU among re-
retreatment TB cases was 2.90 per 100 person-months (95% CI: 1.30-6.45). Participants with 
smear or culture positive pulmonary TB had the highest rate of LTFU (2.76 per 100 person-
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months; 95% CI: 2.02-3.78). The lowest rate was seen among participants with smear and 
culture negative pulmonary TB (1.92 per 100 person-months; 95% CI: 1.16-3.18). Participants 
who received treatment at clinics with a low patient burden had a higher incidence rate of LTFU 
(2.57 per 100 person-months; 95% CI: 1.90-3.48) than participants who were treated at clinics 
with a high patient burden (2.46 per 100 person-months; 95% CI: 1.75-3.46).  
 
Table 3.6: Survival analysis: Time to LTFU among HIV-uninfected TB patients 
Factor Losses to 
follow-up 
(n) 
Person-
months of 
follow-up 
Rate (per 
100 person-
months) 
95% CI  p-value 
Age at TB diagnosis 0.227 
18-34 44 1 576 2.79 2.08-3.75 
35+ 31 1 408 2.20 1.55-3.13 
Gender 0.974 
Male  45 1 765 2.55 1.90-3.41 
Female 30 1 205 2.49 1.74-3.56 
Episode type 0.789 
New 69 2 778 2.48 1.96-3.14 
Re-treatment 6 207 2.90 1.30-6.45 
TB site, smear and culture status *  0.441 
A 39 1 413 2.76 2.02-3.78 
B 15 782 1.92 1.16-3.18 
C 21 790 2.66 1.73-4.08 
Patient burden at treatment clinic 0.883 
Low 42 1 633 2.57 1.90-3.48 
High 33 1 340 2.46 1.75-3.46 
* A: Pulmonary smear or culture positive; B: Pulmonary smear and culture negative; C: Non-
pulmonary 
 
3.5 Cox proportional hazards regression 
Table 3.7 shows the results of the univariate Cox proportional hazards regression analysis. 
None of the variables investigated had a significant association with LTFU. The probability of 
LTFU was lower in participants aged 35 years and older (HR 0.75; 95% CI: 0.47-1.20; p-value: 
0.229) than in participants aged 18-34 years. The probability of LTFU was only one percent 
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lower in female participants than male participants. Participants with a re-treatment TB episode 
had a 12% higher probability of LTFU than in participants with a new TB episode. Participants 
with smear and culture negative pulmonary TB had the lowest probability of LTFU (HR: 0.68; 
95% CI: 0.38-1.24; p-value: 0.208). The probability of LTFU in participants who received 
treatment at clinics with a high patient burden was 3% lower than in participants treated at 
clinics with a low patient burden. 
 
Table 3.7: Results of the univariate Cox proportional hazards regression analysis 
Factor Hazard ratio 95% CI p-value 
Age at TB diagnosis  
18-34 1 (base) 
35+ 0.75 0.47-1.20 0.229 
Sex  
Male  1 (base) 
Female 0.99 0.62-1.58 0.974 
Episode type  
New 1 (base) 
Re-treatment 1.12 0.49-2.59 0.789 
TB site, smear and culture status *  
A 1 (base) 
B 0.68 0.38-1.24 0.208 
C 0.85 0.50-1.46 0.564 
Patient burden at treatment clinic  
Low  1 (base) 
High 0.97 0.61-1.53 0.883 
* A: Pulmonary smear or culture positive; B: Pulmonary smear and culture negative; C: Non-
pulmonary 
 
Table 3.8 shows the results of the multivariate Cox proportional hazards regression analysis. 
Age and sex were included in the adjusted analysis. Participants aged 35 years and above had 
a 25% (95% CI: 0.47-1.19; p = 0.225) lower risk of LTFU than participants aged 18-34 years 
and below. The risk of LTFU among female participants was slightly lower than that among 
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male participants (HR 0.95; 95% CI: 0.64-1.53; p = 0.976). No confounding or interaction was 
observed. The proportional hazards assumption of the model was satisfied (p = 0.212). 
 
Table 3.8: Results of the multivariate Cox proportional hazards regression analysis to 
find factors associated with LTFU (N=467) 
Factor Hazard ratio 95% CI  p-value 
Age at TB diagnosis 
18-34 1 (base) 
35+ 0.75 0.47-1.19 0.225 
Sex 
Male 1 (base) 
Female 0.95 0.60-1.52 0.846 
 
3.6 Sensitivity analyses 
The results of the sensitivity analyses for the regression analyses are presented in Tables 3.9 - 
3.11. 
 
Analysis 1 
For the logistic regression, the results (presented in Table 3.9) showed that excluding the 
possible data errors does not change the results. Possible data errors were excluded by 
censoring analysis at 8 months. The estimated odds ratios, 95% CIs and p-values were exactly 
the same in the 8 and 12-month analysis.  
 
Analysis 2 
The results of sensitivity analysis 2 are shown in Table 3.10. For the Cox proportional hazards 
regression, 68 and 75 participants experienced LTFU for the 8-month and 12-month follow-up 
periods respectively. The results were similar but not identical for age at TB diagnosis. The 
hazard ratios were identical, but the 95% CIs and the p-values were different. In the uncensored 
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analysis, the female participants had a 5% lower risk of LTFU compared to the male 
participants, while in the censored analysis, the female participants had a 5% higher risk of 
LTFU compared to the male participants.   
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Table 3.9: Results of the sensitivity analysis for the multivariate logistic regression. Data were either not censored (12 months follow-up) or 
were censored at 8 months of follow-up. 
Factor Adjusted odds 
ratio (not 
censored) 
Adjusted odds 
ratio (censored) 
95% CI (not 
censored) 
95% CI 
(censored) 
p-value (not 
censored) 
p-value 
(censored) 
Age at TB diagnosis 
18-34 1 (base) 
35+ 0.73 0.73 0.45-1.16 0.45-1.16 0.183 0.183 
Sex 
Male 1 (base) 
Female 0.89 0.89 0.55-1.42 0.55-1.42 0.620 0.620 
 
Table 3.10: Results of the sensitivity analysis for the multivariate Cox proportional hazards regression. Data were either not censored (12 
months follow-up) or were censored at 8 months of follow-up. 
Factor Hazard ratio 
(not censored) 
Hazard ratio 
(censored) 
95% CI (not 
censored) 
95% CI 
(censored) 
p-value (not 
censored) 
p-value 
(censored) 
Age at TB diagnosis 
18-34 1 (base) 
35+ 0.75 0.75 0.47-1.19 0.46-1.22 0.225 0.245 
Sex 
Male 1 (base) 
Female 0.95 1.05 0.60-1.52 0.65-1.71 0.846 0.834 
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Analysis 3 
Table 3.11 shows the results of the sensitivity analysis conducted around the definition of 
LTFU. In both analyses, female participants and participants over the age of 35 years had a 
lower risk of LTFU than male participants and participants ages 18-34 years respectively. 
When only participants who were assigned the outcome default in the primary study were 
considered lost to follow-up, sex was significantly associated with LTFU. Female participants 
had a 66% lower risk of LTFU compared to male participants. Participants with pulmonary 
smear and culture negative had a statistically significant lower risk of LTFU compared to 
participants with pulmonary smear or culture positive TB. However, goodness of fit of the 
model was not observed (p = 0.016).  
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Table 3.11: Results of the sensitivity analysis around the definition of LTFU. The results of multivariate logistic regression conducted when 
participants whose treatment outcomes in the primary study were default and missing were considered lost to follow-up were compared to 
multivariate logistic regression conducted when only those whose outcome in the primary was default. (N = 513) 
Factor Adjusted odds 
ratio (default + 
missing) 
Adjusted odds 
ratio (defaulted 
only) 
95% CI (default 
+ missing) 
95% CI 
(defaulted only) 
p-value (default 
+ missing) 
p-value 
(defaulted only) 
Age at TB diagnosis 
18-34 1 (base) 
35+ 0.73 0.81 0.45-1.16 0.38-1.75 0.183 0.594 
Sex 
Male 1 (base) 
Female 0.89 0.34 0.55-1.42 0.13-0.85 0.620 0.022 
TB site, smear and culture status* 
A 1 (base) 
B - 0.28 - 0.08-0.98 - 0.047 
C - 0.69 - 0.28-1.69 - 0.415 
* A: Pulmonary smear or culture positive; B: Pulmonary smear and culture negative; C: Non-pulmonary 
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CHAPTER 4: DISCUSSION 
The purpose of the discussion is to discuss the results obtained in this study and compare them 
to previously published results in the literature. The limitations of the study, conclusions and 
recommendations will also be presented be in this chapter.  
 
The aim of this study was to determine the demographic and clinical factors associated with 
LTFU in HIV-uninfected TB patients who registered for TB treatment in Ekurhuleni North 
sub-district from 1st January 2011 to 30th June 2012.  
 
Summary of findings 
The results of this study show that LTFU is common among HIV-uninfected TB patients in 
Ekurhuleni North sub-district. Seventeen percent of the study participants were lost to follow-
up during TB treatment using the broader definition of default and no treatment outcome as 
LTFU. LTFU was found to occur throughout TB treatment. None of the factors investigated 
were significantly associated with LTFU. When using the definition of default only as LTFU 
(for the sensitivity analysis), the rate of LTFU was 5.63% and was associated with participant’s 
sex. Female participants had a 66% lower risk of LTFU than male participants. 
 
Burden of LTFU 
The rate of LTFU in this study was 17%, which was higher than the WHO’s acceptable rate of 
LTFU during TB treatment of 5% (Belchior et al., 2016). The rate of LTFU in Ekurhuleni (for 
HIV-infected and uninfected patients) was 4.6% among patients with new, smear positive 
pulmonary TB in 2014 (Massyn et al., 2016). Our study involved HIV-uninfected patients with 
smear positive and negative pulmonary TB, EPTB and new and retreatment TB cases. As the 
participants in this study had a range of TB infection types, the observed rates of LTFU would 
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be higher than those previously published by Massyn et al. (2016). Only 18 of 32 treatment 
clinics in Ekurhuleni North were selected for the study. Selecting these 18 clinics may have 
resulted in the selection of clinics that have higher rates of LTFU. Furthermore, the use of a 
more inclusive definition of LTFU may have contributed to the high rate of LTFU observed, 
as more participants experienced LTFU when we used the expanded definition of LTFU. 
 
The high rate of LTFU observed was unexpected as HIV-infected TB patients have a higher 
risk of LTFU than HIV-uninfected TB patients (Ifebunandu and Ukwaja, 2012, Muture et al., 
2011) and this study did not involve any HIV-infected participants. Pepper et al. (2012) 
proposed that HIV-infected TB patients may have improved follow-up as regular clinic 
attendance is required on ART to avoid life-threatening illness. In stark contrast to the ART 
programme, the preparation of patients to receive TB treatment is minimal and is not 
standardised (Dong et al., 2007). HIV-uninfected TB patients may, therefore, have a lower 
understanding of the importance of remaining on TB treatment.  
 
The three districts with the highest incidence rates of TB in South Africa in 2015 had more 
than 900 incident cases per 100 000 population, and had LTFU rates of 7.3-8.8% (Massyn et 
al., 2016). The rate of LTFU observed in this study was most similar to the rate of LTFU in ZF 
Mgcawu district in Northern Cape Province (16.5%), which had 856 incident cases of TB per 
100 000 population (Massyn et al., 2016). When only default was used as LTFU in the 
sensitivity analysis, a lower rate of LTFU than that in the three districts was observed. This rate 
of LTFU (5.63%) can be considered to be the minimum rate of LTFU for this study. The 
maximum rate of LTFU, 17%, was much higher than the minimum rate. The inability to 
confirm the treatment outcome of the 60 participants classified as LTFU due to a missing 
treatment outcome and possible differences in the capacities of districts to trace patients may 
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explain the differences in LTFU rates. The districts with high incidence rates of TB may invest 
more money into tracing TB patients, which may explain the lower rates of LTFU observed.   
 
The rates of LTFU observed in this study were much higher than those found in other countries. 
The national average LTFU rate in Benin is 1% (Ade et al., 2016). Benin has achieved a 1% 
LTFU rate through interventions such as nutritional support and the use of a special Basic 
Management Unit that traces patients that miss DOTS sessions and other scheduled 
appointments (Ade et al., 2016). LTFU rates in Kenya ranged from 5.5% in a study using 
national data (Sitienei et al., 2015) to 13.3% in an urban informal settlement (Kizito et al., 
2011). Ten percent LTFU was observed in a study conducted in Southern Mozambique 
(García-Basteiro et al., 2016). LTFU rates were 14% in Kampala, Uganda (Sendagire et al., 
2012) and in Brazil (Garrido et al., 2012). In Europe, a study in Russia observed a 4.6% rate of 
LTFU (Jakubowiak et al., 2009) and one in Belarus a rate of 13% (Khaliaukin et al., 2014). 
Differences in TB disease burden, health policy and economic factors may account for the 
differences in the rates of LTFU. In countries with a low burden of TB disease, it may be easier 
to trace patients that have missed TB treatment appointments, while health policies may inform 
how countries deal with LTFU. Poor or non-existent policies are likely to result in an increase 
in rates of LTFU. Economic factors may increase the burden of LTFU if TB patients are unable 
to afford to miss work or buy nutritional supplements.     
 
More study participants were aged 18-34 years than 35 years and above. The highest number 
of TB notifications are among 20-40 year olds (Wood et al., 2010). Younger people may be 
more susceptible to be TB due to behaviour patterns, migration due to work and a low 
socioeconomic status that influences exposure to poor housing conditions. No differences in 
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median age were observed among those who were lost to follow-up and those who were not 
lost to follow-up in the two age categories in this study.  
 
Although a higher proportion of participants aged 18-34 were lost to follow-up compared to 
those aged 35 years and older, the difference was not statistically significant. A previous study 
in Ghana found that LTFU rates were significantly higher in younger participants than older 
participants (Dodor, 2004). Younger participants may have higher rates of LTFU as following 
migration for work they may lose the support systems they had prior to migrating, which 
increases their risk of LTFU (Kulkarni et al., 2013). Peer pressure is likely to be a more 
significant contributing factor to LTFU in younger people than older people as group norms 
affect treatment adherence (Martin et al., 2005). Younger TB patients may feel that to fit in and 
be accepted by their peers they cannot continue TB treatment. 
 
Although the majority of those lost to follow-up in this study were male, no significant 
difference in LTFU was found between male and female participants. A previous study found 
that men were more likely to experience LTFU than women, probably due to men shunning 
healthcare services more than women (Belchior et al., 2016). The stigma associated with TB 
and societal expectations may prevent men from seeking or remaining in care as they may not 
want to be perceived as weak or ill. In families where the male TB patient is the primary 
breadwinner, seeking care may mean a loss of income for the family. In Kenya, many male TB 
patients who experienced LTFU worked as casual workers so they did not have the benefit of 
sick leave (Kizito et al., 2011). The same may be true in Ekurhuleni North, leading men to opt 
to abandon treatment in order to provide for their families. Expenses associated with care can 
increase poverty and increase the risk of poor outcomes (Saunders and Evans, 2016). In 
Ekurhuleni, men are breadwinners in 69% of households (Statistics South Africa, 2016). A 
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study in Pakistan found that patients who stopped treatment early felt guilty about the negative 
effects that their diagnosis and treatment would have on their families (Chida et al., 2015).  
 
Participants with a retreatment TB episode had a higher rate of LTFU than participants with a 
new TB episode, but the difference was not statistically significant. Previous studies involving 
HIV-infected and uninfected TB patients found that LTFU was higher in retreatment TB cases 
compared to new cases TB cases (Kigozi et al., 2017, Pardeshi, 2010). In the study by Kigozi 
et al. (2017), participants with retreatment TB were twice more likely to be lost to follow-up 
than participants with a new TB episode. Maximum LTFU occurred earlier in new cases 
compared to retreatment cases (Pardeshi, 2010), suggesting that the retreatment TB patients 
had a better understanding of the importance of remaining on TB treatment. Similar results 
were observed in this study, with maximum LTFU occurring in the first two months of 
treatment for new TB cases and two to five months into treatment for retreatment TB cases 
(results not shown). 
 
TB patients with retreatment TB may do their best to remain on TB treatment for a longer 
period of time as they have had at least two TB treatment counselling sessions (one at the 
beginning of each treatment episode) which may increase their understanding of treatment. A 
desire to obtain a good treatment outcome in their second round of treatment may also motivate 
them to remain on treatment longer than TB patients with a new TB episode. However, if the 
circumstances that led to the participants with retreatment TB leaving treatment prematurely 
initially have not changed, they are likely to fail to adhere to treatment again. 
 
It was expected that participants with EPTB would have higher rates of LTFU than participants 
with pulmonary TB. However, no significant difference in LTFU was observed. Although 
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treatment for drug sensitive pulmonary TB normally lasts six to eight months, participants with 
EPTB may be on treatment for extended periods of time. Some treatment experts prefer patients 
to remain on treatment for at least 12 months or until there is pathological or radiological 
evidence of disease regression (Lee, 2015).  
 
For some participants that were on TB treatment for more than one year, it is possible that the 
participants were lost to follow-up during treatment, but later returned and that this was not 
indicated in the original records. The continuation phase in TB treatment is normally 4 months 
long, but TB patients who have cavitary pulmonary disease, a positive sputum test at 2 months 
or are not treated with pyrazinamide during the intensive phase will have a 7-month long 
continuation phase (CDC, 2016). The data used in this study did not indicate whether or not 
this was the case for the participants who had extended treatment periods.  
 
The patient burden at treatment clinic did not affect rates of LTFU, as the rates of LTFU were 
similar between low and high patient burden clinics. This was surprising as a study conducted 
in South Africa on HIV found that treatment facilities with large numbers of patients can 
provide high-quality care as they would have more staff than facilities with fewer patients and 
the types of staff would be different (MacLeod et al., 2016). An example is that the large 
facilities are more likely to have specialist services. The clinics with high patient burdens may 
be prioritised when health planning occurs, receiving more human and financial resource 
allocations for patient care. Inadequate numbers of staff and resources can have a negative 
impact on the retention of patients in care. LTFU in South Africa may be driven by the history 
of neglect, poor patient management (likely due to constraints on healthcare workers) and 
fragmented health services (Weyer, 2007). 
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Timing of LTFU 
LTFU was found to occur throughout TB treatment. Although the highest proportion of LTFU 
occurred in the first two months of TB treatment, LTFU was occurring at all times during the 
follow-up period with a steady increase in risk over the first six months of follow-up. LTFU 
will occur throughout treatment as at each point in the treatment period there are different 
factors that influence LTFU. During the intensive phase of treatment, being older than 45 years, 
the inconvenience of the treatment programme, work related problems and being symptom free 
can increase the risk of LTFU (Chandrasekaran et al., 2005). In the continuation phase of 
treatment, feeling better or worse can influence a patient to abandon treatment, as well as 
follow-up tests not being conducted (Akessa et al., 2015). TB patients may think that improved 
symptoms mean that they have been cured of TB (Dodor, 2004). Patients may also be 
demotivated by the length and complexity of treatment (Kruk et al., 2008, Martin et al., 2005).   
 
Time to LTFU varies in different countries and settings, with studies reporting median times 
to LTFU ranging from 1.6 months to 4.1 months (Hoa et al., 2012, Ifebunandu and Ukwaja, 
2012, Jenkins et al., 2013). The differences in median times to LTFU can be attributed to a 
variation in the factors influencing LTFU in different settings. As an example, residing in an 
urban residence in Morocco is significantly associated with LTFU while in Nigeria, a rural 
residence increases the risk of LTFU (Tola et al., 2015). Differences in TB treatment protocols 
may also influence this difference. In Ghana, different facilities are used in the intensive and 
continuation phases of treatment (Dodor, 2004). The change in treatment facility may cause 
confusion or be inconvenient for the patient. The change may also make it difficult for 
healthcare workers to trace patients that have stopped receiving treatment. In South Africa, the 
same treatment facility is used for all stages of treatment unless the patient transfers out. 
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None of the variables investigated had a statistically significant effect on time to LTFU. A 
previous study found that TB patients who received treatment at public facilities, male TB 
patients and retreatment after LTFU TB patients had significantly shorter times to LTFU 
(Masini et al., 2016). Factors that were not investigated in this study may have had an effect 
on the time to LTFU in Ekurhuleni North sub-district. 
 
There was collinearity between the main outcome, LTFU, and length of treatment and change 
of treatment phase. Participants who are lost to follow-up during TB treatment are expected to 
have shorter treatment times, and so are less likely to change treatment phase. The two 
variables, length of treatment and change of treatment phase, are also outcomes of TB 
treatment, and so cannot be treated as factors in regression analysis. Forty-two percent of the 
participants who were lost to follow-up changed treatment phase during TB treatment.  
 
Change of treatment phase was not a confounder in this study. A confounder is a risk factor 
that is associated with the outcome of interest as well as the exposure but is not a result of the 
exposure. TB patients begin treatment, change treatment phase after 2 months, then continue 
treatment until its completion. As a change of treatment phase is on the pathway from start of 
treatment to treatment completion, it cannot occur without treatment initiation, nor can TB 
treatment be completed without a change of treatment phase. As a result, change of treatment 
phase is not a confounder. In research studies, confounders can be dealt with by using matching 
in the design phase or by using stratification or adjustment in the data analysis phase. As 
secondary data analysis was used in this study, the only options for dealing with any 
confounders were stratification or adjusting for the confounder in regression analysis. Given 
that the change of phase was not a confounder, adjusting for it in regression analysis was not 
necessary.  
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Factors associated with LTFU 
No factors in this study were found to be significantly associated with LTFU. None of the 
factors had a p-value of less than 0.2 in univariate regression analysis, so only age and sex were 
included in multivariate logistic regression a priori. Cox proportional hazards regression 
analysis gave similar results to logistic regression analysis.  
 
In some previous studies, the factors investigated in this study were found to influence LTFU. 
Gafar et al. (2014) found that age was significantly associated with LTFU. Men had a higher 
risk of LTFU than women in Argentina (Herrero et al., 2015). Episode type was significantly 
associated with LTFU, with patients with a retreatment episode of TB having a higher risk of 
LTFU than those with a new TB episode (Cherkaoui et al., 2014). Patients with EPTB had a 
higher risk of LTFU than participants with pulmonary TB (Hoa et al., 2012), and the enrolment 
of a large number of patients (more than one hundred) in a TB treatment programme was found 
to promote LTFU (Moyo et al., 2015).  
 
On the other hand, similar results to the ones obtained in this study were found in some studies. 
Akessa et al. (2015) did not observe a significant association between age, sex and LTFU. 
Episode type did not affect LTFU in a study by Sanchez-Padilla et al. (2014), nor did type of 
TB in another (Nglazi et al., 2015). 
 
The limited number of variables and the missing data may have contributed to the failure to 
find factors associated with LTFU in this study. It is possible that the factors that are 
significantly associated with LTFU in Ekurhuleni North sub-district among HIV-uninfected 
TB patients were not investigated in this study. Adherence to TB treatment is a complex and 
dynamic phenomenon as many factors affect treatment taking behaviour (Ershova et al., 2014). 
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It is important to establish what factors lead to LTFU in a particular setting in order to have 
effective interventions. 
 
Methodological issues 
In both logistic regression and Cox proportional hazards regression, none of the factors 
investigated were significantly associated with LTFU. The trends observed with logistic 
regression analysis, for example, women having a lower risk of LTFU than men, were observed 
with Cox proportional hazards regression. There was however one exception. In univariate 
logistic regression analysis, participants with non-pulmonary TB had a higher risk of LTFU 
compared to participants with pulmonary smear or culture positive TB. However, in univariate 
Cox proportional hazards regression, participants with non-pulmonary TB had a lower risk of 
LTFU. 
 
A possible reason for the differences observed with logistic and Cox proportional hazards 
regression is that the two regression methods are different. Logistic regression models are fully 
parametric while Cox proportional hazards regression models are semiparametric. Logistic 
regression analysis will give a response toward the beginning of follow-up equal weight with 
a response towards the end of analysis (Moriguchi et al., 1993). The Cox model, on the other 
hand, will incorporate the covariates measured on each individual and will use the response 
time in analysis (Moriguchi et al., 1993). The assumptions for the two models are different. 
Logistic regression assumes independent observations, while Cox proportional hazards 
regression assumes that censoring is independent of the time to event, proportional hazards and 
independent observations. 
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Sensitivity analysis was conducted for the multivariate logistic regression and Cox proportional 
hazards regression. Sensitivity analysis is used to estimate the effect bias could have on an 
estimate by simulating different scenarios. It has been described as “the last line of defence 
against biases after every effort has been made to eliminate, control or reduce them in study 
design, data collection and data analysis” (Schneeweiss, 2006). It is important to test the 
assumptions used in the design of a study as these assumptions may influence the results if they 
are not met (Thabane et al., 2013). Consistency in the results obtained strengthens the 
credibility of the findings (Thabane et al., 2013).  
 
The logistic regression results are consistent and can, therefore, be considered credible. The 
results of the Cox proportional hazards regression sensitivity analysis are different for the 
participant’s sex. Female participants had a 5% lower risk of LTFU compared to male 
participants in the uncensored analysis and a 5% higher risk of LTFU in the censored analysis. 
The difference observed may be due to the fact that in the censored Cox proportional hazards 
regression analysis, only 68 participants experienced LTFU, compared to 75 in the uncensored 
analysis.  
 
The sensitivity analysis conducted around the definition of LTFU gave different results to the 
main analysis. Although sex was significantly associated with LTFU, goodness of fit of the 
model was not observed. This result means that the model gives a poor fit of the data. The 
inability of the model to accurately predict LTFU may be due to the large number of missing 
outcomes. The results obtained in the two analyses are not consistent with one another and 
emphasise the need for complete and accurate records in TB programmes.  
 
53 
 
Limitations 
Several limitations were identified. One limitation in this study was that LTFU was treated as 
an event instead of a process. LTFU was assumed to occur on the date of the most recent clinic 
visit. However, as patients would have collected their treatment on this date, it is possible that 
the patients only stopped taking their medication a few days or weeks after their most recent 
clinic visit. Using the next scheduled clinic visit date as the date of LTFU would have been 
more accurate but these data were not collected. 
 
No information was available on what the clinics did to trace the patients that had been lost to 
follow-up. It is possible that the patients had transferred to another clinic or had died. 
Knowledge of this is important to evaluate TB treatment programmes and plan effectively. 
This information will also help researchers to accurately determine the rate of LTFU as well as 
the factors that contribute to LTFU.  
 
As this study involved secondary data analysis, the study question asked in this study was 
different from the question that was asked in the primary study. As a result, the variables 
collected in the primary study were different from the variables required in this study. This 
study had a limited number of variables, so information on socioeconomic status, residence 
type, comorbidities, treatment clinics and health system factors was not available. As the 
primary study focused on Ekurhuleni North, no data on other parts of South Africa was 
available, so the study results may not be generalizable to other parts of South Africa. Data 
may have been more incomplete for patients whose illness was more advanced due to 
hospitalization in a different area or transfer.  
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Another limitation in this study was missing data. Some variables could not be used as there 
were not enough responses collected. The missing data in some of the variables used may have 
affected the results. There may also have been errors in data extraction that could not be 
detected or corrected. Errors in documenting TB treatment may have occurred. It is possible 
that some of the errors in the treatment dates observed are due to errors at the treatment clinics. 
Some patients may have been receiving care at the clinics in this study but not actually 
registered until long after commencing treatment. Some patients may not have been registered 
at all due to health system factors, so data related to their treatment would not have been 
available for this study.  
 
Our study was not designed to measure initial LTFU, which is a major problem in South Africa. 
Initial LTFU is LTFU that occurs before the beginning of treatment (Massyn et al., 2016). 
Initial LTFU rates in South Africa range from 4.5% to 38%, depending on the location, 
treatment settings and whether the data is electronically verified or extracted manually from a 
TB register (Cele et al., 2016). 
 
Conclusions and Recommendations 
LTFU is a common phenomenon in HIV-uninfected patients in Ekurhuleni North sub-district 
and occurs at all times during TB treatment. Age, sex, episode type, patient burden at treatment 
clinic and TB site, smear and culture status have no statistically significant effect on LTFU 
among HIV-uninfected TB patients in Ekurhuleni North sub-district. 
 
It is recommended that studies are conducted to determine the factors influencing LTFU during 
TB treatment in South Africa with a focus on HIV-uninfected TB patients. HIV-uninfected TB 
patients are a neglected cohort in treatment planning. Increased attention to the needs of this 
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group is recommended. Educating the public about TB will help to reduce stigma and therefore 
LTFU. National statistics should also include pre-treatment LTFU to allow for a more accurate 
picture of LTFU in South Africa. Finally, ensuring adequate financial and human resource 
support to treatment clinics is also recommended to reduce LTFU and enabling tracing of TB 
patients in Ekurhuleni North.    
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Table A1: List of variables and the coding used  
Variable Coding/Format 
Participant ID Number  
Age at TB diagnosis (years) Continuous  
Age at TB diagnosis (years) 0: 18-34 
1: 35+ 
Length of treatment (months) Continuous  
Length of treatment (months) 0: Less than 6 months 
1: 6-9 months 
2: 9-12 months 
97: Unknown/missing 
Time to LTFU (months) Continuous  
Time to LTFU (months) 0: Less than 2 months 
1: 2-4 months 
2: 4-6 months 
3: 6-12 months 
97: Unknown/missing 
Time to change of treatment phase 
(months) 
Continuous  
Time to change of treatment phase 
(months) 
0: Less than 2 months 
1: 2-4 months 
2: 4-6 months 
3: 6-12 months 
97: Unknown/missing 
Sex 1: Male 
2: Female 
Episode type 1: New 
2: Re-treatment 
TB site, smear and culture status 1: Pulmonary smear or culture positive 
2: Pulmonary smear and culture negative 
3: Non-pulmonary 
Change of treatment phase 0: No 
1: Yes 
3: Unknown/missing 
Treatment outcome 1: Success 
3: LTFU 
4: MDR-TB 
6: Death 
7: Treatment failure 
Success or poor outcome 1: Success 
2: Poor outcome 
Loss to follow-up 0: No LTFU 
1: LTFU 
Treatment clinic 3: A  
4: B  
5: C  
6: D  
8: E  
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Variable Coding/Format 
9: F  
11: G  
12: H  
14: I  
15: J  
16: K  
17: L  
22: M  
24: N  
27: O  
29: P  
30: Q  
31: R  
Patient burden at treatment clinic 1: Low burden 
2: High burden 
Treatment start date Date 
Date of change of treatment phase Date 
Date of most recent clinic visit Date 
Date of treatment completion Date 
Exit date Date 
 
 
 
 
 
 
 
